Follistatin-344 regulatory status
Current status of Follistatin-344 in the United States: Unscheduled. In sport: WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
What is the current status of Follistatin-344?
Regulatory: UnscheduledWADA: WADA prohibitedVerified: Verified Sep 22, 2026
- FDA and compounding
- Follistatin-344 has never been submitted to or reviewed by FDA as a drug and does not appear on the 503A bulk drug substance Category 1, 2, or 3 lists or the 503B bulks list as of the last verification date. It is a biologic sized protein rather than a small peptide, so even a nomination would face the biologics compounding limits. There is no approved product and no federal basis to compound it; products sold online are labeled for research use only.
- WADA
- WADA prohibited
- Access path
- Not legally available for human use in the United States: no FDA approved product and no federal basis to compound it from bulk.
- Gene therapy form (AAV1-FS344) was available only inside registered clinical trials.
- Products labeled research use only are unapproved drugs when sold for human use and are not verified.
Full Follistatin-344 page: evidence, dosing in the literature, and sources
How has the status of Follistatin-344 changed over time?
No dated regulatory event has been recorded for Follistatin-344. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Follistatin-344 and the source of each dated event.
- [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [2]WADA Prohibited List, section S4 hormone and metabolic modulators (names follistatin as a myostatin binding protein)WADA, 2026
- [3]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026